Evidence map›Paper›PMID 30080852›Full record

SynthesisPLoS neglected tropical diseases2018

A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.

Jolynne Mokaya, Anna L McNaughton, Martin J Hadley, Apostolos Beloukas, Anna-Maria Geretti, Dominique Goedhals, Philippa C Matthews

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 3 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Prevalence of Hepatitis B Virus Markers among the Women with Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Hepatitis B eradication: vaccine as a key player.American journal of translational research · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jolynne MokayaNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-8398-0689
Anna L McNaughtonNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Martin J HadleyOxford University Academic IT Department, Oxford, United Kingdom.ORCID 0000-0002-3039-6849
Apostolos BeloukasInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0001-5639-0528
Anna-Maria GerettiInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Dominique GoedhalsDivision of Virology, University of the Free State/National Health Laboratory Service, Bloemfontein, Republic of South Africa.
Philippa C MatthewsNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-4036-4269
University of Oxford · GBUniversity of Liverpool · GBJohn Radcliffe Hospital · GBNational Health Laboratory Service · ZA

Funding

Wellcome Trust 110110
6 · The paper itself

Abstract

International sustainable development goals for the elimination of viral hepatitis as a public health problem by 2030 highlight the pressing need to optimize strategies for prevention, diagnosis and treatment. Selected or transmitted resistance associated mutations (RAMs) and vaccine escape mutations (VEMs) in hepatitis B virus (HBV) may reduce the success of existing treatment and prevention strategies. These issues are particularly pertinent for many settings in Africa where there is high HBV prevalence and co-endemic HIV infection, but lack of robust epidemiological data and limited education, diagnostics and clinical care. The prevalence, distribution and impact of RAMs and VEMs in these populations are neglected in the current literature. We therefore set out to assimilate data for sub-Saharan Africa through a systematic literature review and analysis of published sequence data, and present these in an on-line database (https://livedataoxford.shinyapps.io/1510659619-3Xkoe2NKkKJ7Drg/). The majority of the data were from HIV/HBV coinfected cohorts. The commonest RAM was rtM204I/V, either alone or in combination with associated mutations, and identified in both reportedly treatment-naïve and treatment-experienced adults. We also identified the suite of mutations rtM204V/I + rtL180M + rtV173L, that has been associated with vaccine escape, in over 1/3 of cohorts. Although tenofovir has a high genetic barrier to resistance, it is of concern that emerging data suggest polymorphisms that may be associated with resistance, although the precise clinical impact of these is unknown. Overall, there is an urgent need for improved diagnostic screening, enhanced laboratory assessment of HBV before and during therapy, and sustained roll out of tenofovir in preference to lamivudine alone. Further data are needed in order to inform population and individual approaches to HBV diagnosis, monitoring and therapy in these highly vulnerable settings.

Indexed as

AfricaAntiviral AgentsDrug Resistance, ViralHepatitis BHepatitis B VaccinesHepatitis B virusHumansAntiviral AgentsHepatitis B Vaccines

Identifiers

PMID30080852
PMCPMC6095632
OpenAlexW2952866173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.